Your browser doesn't support javascript.
loading
Patient-Reported Consequences of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.
Pasquale, Cara B; Vietri, Jeffrey; Choate, Radmila; McDaniel, Angee; Sato, Reiko; Ford, Kimbal D; Malanga, Elisha; Yawn, Barbara P.
Afiliação
  • Pasquale CB; Research Department, COPD Foundation, Inc., Washington, D.C.
  • Vietri J; Patient & Health Impact, Pfizer, Inc., Collegeville, Pennsylvania.
  • Choate R; College of Public Health, University of Kentucky Lexington, and Consultant, COPD Foundation, Inc.
  • McDaniel A; Medical Affairs, Pfizer, Inc., Columbia, Missouri.
  • Sato R; Patient & Health Impact, Pfizer, Inc., Collegeville, Pennsylvania.
  • Ford KD; Medical Affairs, Pfizer, Inc., Lexington, Kentucky.
  • Malanga E; Research Department, COPD Foundation, Inc., Washington, D.C.
  • Yawn BP; Research Department, COPD Foundation, Inc., Washington, D.C.
Chronic Obstr Pulm Dis ; 6(2): 132-144, 2019 Apr 09.
Article em En | MEDLINE | ID: mdl-30974053
ABSTRACT
Community acquired pneumonia (CAP) carries high morbidity, mortality, and economic burden, which is even higher in adults diagnosed with chronic obstructive pulmonary disease (COPD). While several studies have assessed the clinical burden and mortality risk of CAP and COPD, very few studies focus on CAP burden from a COPD patient perspective. Individuals recently diagnosed with CAP and with pre-existing COPD were recruited through the COPD Foundation. The CAP Burden of Illness Questionnaire (CAP-BIQ), a content validated questionnaire assessing CAP symptomatology, duration of symptoms and CAP impact on work, activities and family, was administered at baseline and at 30-days follow-up. Of the 490 participants recruited, 481 had data sufficient for analysis. The prevalence of respiratory-related symptoms was very high (>90%) at the time of diagnosis with other generalized symptoms such as fatigue, trouble sleeping, headaches and confusion present in more than 60% of participants. Mean duration of symptoms varied from approximately 2 weeks for headaches and fever to more than a month for fatigue, wheezing, dyspnea, and cough. Employed participants missed an average of 21 days of work and those not employed missed 36 days of usual activities. Over 84% required help from family, friends or care givers. CAP is a serious and burdensome condition for people with COPD, a condition that can impair activities for weeks, frequently requires care from family or friends, and includes lingering symptoms. The patient-reported impact of CAP reported in this study underscores the need for prevention strategies in this population.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article